Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Interruptions

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    373 result(s) found for: Interruptions. Displaying page 1 of 19.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-006055-33 Sponsor Protocol Number: HypoGI Start Date*: 2023-03-05
    Sponsor Name:Medical University of Vienna
    Full Title: Assessing the feasibility of pharmacologically induced hypothyroidism in patients with advanced pancreatic cancer - a pilot study
    Medical condition: Patients with newly diagnosed metastatic pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000431-49 Sponsor Protocol Number: CC220MM002 Start Date*: 2021-10-18
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with...
    Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) NO (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001711-23 Sponsor Protocol Number: ET19-084 Start Date*: 2020-02-03
    Sponsor Name:Centre Léon Bérard
    Full Title: CICA-RT – Phase III randomized multicenter study evaluating Cicaderma® ointment efficacy versus the current practice of each center for the radiation dermatitis prevention in patients with non-meta...
    Medical condition: Breast adenocarcinoma treated with post-operative radiotherapy Post-operative breast cancer radiotherapy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003541-17 Sponsor Protocol Number: FIMHCSBR-2017 Start Date*: 2018-10-24
    Sponsor Name:FIMABIS Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud [...]
    1. FIMABIS Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
    2. APES Costa del Sol (Agencia Pública Empresarial Sanitaria)
    Full Title: Neuropsiquiatric Evolution After Introduction of Raltegravir QD in substitution of dolutegravir: NEAR QD Study
    Medical condition: Human Inmunodeficiency Virus Infection (HIV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006854-17 Sponsor Protocol Number: OPTIMDASATINIB 10/2008 Start Date*: 2009-03-03
    Sponsor Name:CH-Versailles
    Full Title: A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATING THE OPTIMIZATION OF THE RESIDUAL PLASMATIC LEVEL OF DASATINIB (SPRYCEL®) IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKA...
    Medical condition: Chronic phase chronic myelogenous leukaemia (CP-CML).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021665-68 Sponsor Protocol Number: Citrasate01 Start Date*: 2010-10-06
    Sponsor Name:University Hospital Antwerp
    Full Title: Comparison of Slow Efficiency dialysis (SLEDD) with Unfractionated Heparin versus Citrasate in Critically Ill Patients
    Medical condition: To compare the feasability, safety and efficacy of Sustained Slow Efficiency Dialys (SLEDD) using regional anticoagulation with Citrasate compared to systemic anticoagulation with Unfractionated He...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018875 Haemodialysis LLT
    12.1 10052259 Artificial kidney clotting during dialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017943-32 Sponsor Protocol Number: 871 Start Date*: 2010-05-31
    Sponsor Name:Antwerp University Hospital
    Full Title: Study of the combination of gemcitabine, cetuximab and radiotherapy in patients with head and neck cancer
    Medical condition: Histologically confirmed squamous cell carcinoma of the head and neck which qualifies for definitive treatment with chemoradiation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067821 Head and neck cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004728-39 Sponsor Protocol Number: AURORA Start Date*: 2020-07-31
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
    Full Title: A Phase II, non-randomized, single arm, translational study of CAbozantinib for Patients with HepatocellUlaR CarcinOma (HCC) Refractory to first line TreAtment
    Medical condition: Locally advanced or metastatic and/or unresectable HCC
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001426-17 Sponsor Protocol Number: 1M Start Date*: 2018-01-03
    Sponsor Name:University Hospitals Leuven (Gasthuisberg)
    Full Title: Tranexamic Acid to reduce bleeding in patients treated with new oral anticoagulants undergoing dental extraction (EXTRACT-NOAC)
    Medical condition: Patients treated with a NOAC, aged 18 years or older undergoing dental extraction
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000087-42 Sponsor Protocol Number: TAISTR_2016 Start Date*: 2016-05-11
    Sponsor Name:University College Dublin
    Full Title: A multicentre, prospective, single arm, open-label 96 week observational trial of the tolerability, adherence and efficacy of a dolutegravir/abacavir/lamivudine single tablet regimen in HIV-1 antib...
    Medical condition: Human Immunodeficiency Virus (HIV) infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000607-36 Sponsor Protocol Number: ACE-536-MF-002 Start Date*: 2021-06-01
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOM...
    Medical condition: Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074692 Post essential thrombocythaemia myelofibrosis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) AT (Trial now transitioned) IE (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005061-13 Sponsor Protocol Number: A011-12 Start Date*: 2021-06-22
    Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA
    Full Title: An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) AT (Ongoing) PT (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000199-12 Sponsor Protocol Number: A011-13 Start Date*: 2022-07-19
    Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and Hig...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) SE (Prematurely Ended) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003190-34 Sponsor Protocol Number: ACE-536-MDS-002 Start Date*: 2019-01-02
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Ris...
    Medical condition: Myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) LT (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) BE (Ongoing) PL (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000845-15 Sponsor Protocol Number: GCT3013-02 Start Date*: 2020-08-25
    Sponsor Name:Genmab A/S
    Full Title: A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma
    Medical condition: B-cell Non-Hodgkin Lymphoma Diffuse large B-cell lymphoma Non-Hodgkin lymphoma Follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) CZ (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004738-27 Sponsor Protocol Number: A011-09 Start Date*: 2018-08-15
    Sponsor Name:Acceleron Pharma Inc.
    Full Title: A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonar...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077739 Pulmonary arterial hypertension WHO functional class I LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001318-92 Sponsor Protocol Number: AP24534-15-303 Start Date*: 2015-11-03
    Sponsor Name:ARIAD Pharmaceuticals, Inc.
    Full Title: A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib
    Medical condition: Chronic Phase Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) DK (Prematurely Ended) CZ (Completed) PT (Completed) FR (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000068-30 Sponsor Protocol Number: ECT-001 Start Date*: 2021-12-15
    Sponsor Name:Ectin Research AB
    Full Title: An open-label, multi-center, phase I/II study of MFA-370 in patients with metastatic urothelial cancer
    Medical condition: Metastatic urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) LT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002101-62 Sponsor Protocol Number: HM13/10758 Start Date*: 2014-12-29
    Sponsor Name:University of Leeds
    Full Title: Pomalidomide in relapsed and refractory multiple myeloma (RRMM)
    Medical condition: Relapsed and Refractory Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004083-39 Sponsor Protocol Number: DSMM_XIII Start Date*: 2009-10-19
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation – Hämatologie und Onkologie mbH
    Full Title: The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the treatment of multiple myeloma
    Medical condition: primary treatment of multiple myeloma patients of age 60 till 75 years
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA